Sage Therapeutics to Present at the Leerink Partners Rare Disease Roundtable
September 21 2016 - 4:05PM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced that Jeff Jonas, M.D., Chief Executive Officer of
Sage, will present at the Leerink Partners Rare Disease Roundtable
at 1:05 PM ET on September 28, in New York, NY.
A live webcast of the presentation can be accessed on the
investor page of Sage's website at investor.sagerx.com. A
replay of the webcast will also be archived for up to 30 days on
Sage's website following the conference.
About Sage TherapeuticsSage Therapeutics is a
clinical-stage biopharmaceutical company committed to developing
novel medicines to transform the lives of patients with
life-altering central nervous system (CNS) disorders. Sage has a
portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is
in Phase 3 clinical development for super-refractory status
epilepticus, a rare and severe seizure disorder, and is being
developed for postpartum depression. Sage is developing its next
generation modulators, including SAGE-217 and SAGE-718, with a
focus on acute and chronic CNS disorders.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160921006449/en/
Investor Contact:Sage TherapeuticsPaul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Suda
Communications LLCMaureen L. Suda,
585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2023 to Apr 2024